{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:32:00Z","timestamp":1793197920592,"version":"4.5.0"},"reference-count":29,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Botulinum neurotoxin type A (BoNT-A) injection and augmentation enterocystoplasty (AE) are alternative and effective management strategies for neurogenic detrusor overactivity (NDO) refractory to pharmacotherapy. A great majority of patients with spinal cord injury (SCI) may, however, prefer BoNT-A injections to AE, due to the less invasive characteristics. In this study we evaluated the influence of various video-urodynamic study (VUDS) parameters in SCI patients who continuously received repeat BoNT-A detrusor injections or switched to AE to improve their bladder conditions. We compared the changes in the urodynamic parameters before and after each mode of treatment. In this retrospective study, all SCI patients with refractory NDO who had received at least one BoNT-A injection were enrolled. VUDS was performed before and after both BoNT-A injection and AE. All of the urodynamic parameters of the storage and micturition\u2014including the bladder capacity of every sensation, maximal flow rate (Qmax), post-voiding residual volume, detrusor pressure at Qmax, and bladder contractility index\u2014were recorded. A total of 126 patients, including 46 women and 80 men, with a mean age of 41.8 \u00b1 13.1 years, were recruited for this study. All of the patients receiving either BoNT-A injection or AE had a statistically significant increase of bladder capacity at every time-point during filling and a decrease in detrusor pressure at Qmax during voiding. Patients who switched from BoNT-A to AE had greater improvements in their urodynamic parameters when compared with those who continued with BoNT-A injections. Accordingly, SCI patients receiving BoNT-A injections but experiencing few improvements in their urodynamic parameters should consider switching to AE to achieve a better storage function and bladder capacity.<\/jats:p>","DOI":"10.3390\/toxins14010047","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T22:03:13Z","timestamp":1641852193000},"page":"47","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Video-Urodynamic Characteristics and Predictors of Switching from Botulinum Neurotoxin a Injection to Augmentation Enterocystoplasty in Spinal Cord Injury Patients"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7862-0806","authenticated-orcid":false,"given":"Chih-Chieh","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Urology, Taipei Veterans General Hospital, Taipei 112304, Taiwan"},{"name":"Department of Urology, School of Medicine, College of Medicine, Shu-Tien Urological Research Center, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7165-4771","authenticated-orcid":false,"given":"Hann-Chorng","family":"Kuo","sequence":"additional","affiliation":[{"name":"Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien 970374, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/MOU.0000000000000290","article-title":"Neurourologic dysfunction: Evaluation, surveillance and therapy","volume":"26","author":"Harris","year":"2016","journal-title":"Curr. Opin. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.urology.2015.06.005","article-title":"Urological Surveillance and Medical Complications after Spinal Cord Injury in the United States","volume":"86","author":"Cameron","year":"2015","journal-title":"Urology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"816274","DOI":"10.1155\/2012\/816274","article-title":"Neurogenic bladder","volume":"2012","author":"Dorsher","year":"2012","journal-title":"Adv. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1097\/JU.0000000000002235","article-title":"The AUA\/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Diagnosis and Evaluation","volume":"206","author":"Ginsberg","year":"2021","journal-title":"J. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1757-5672.2010.00076.x","article-title":"Management of Low Compliant Bladder in Spinal Cord Injured Patients","volume":"2","author":"Park","year":"2010","journal-title":"Low Urin. Tract. Sympt."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2011.07.001","article-title":"Contemporary management of lower urinary tract disease with botulinum toxin A: A systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA)","volume":"60","author":"Mangera","year":"2011","journal-title":"Eur. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.eururo.2003.12.004","article-title":"European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity","volume":"45","author":"Reitz","year":"2004","journal-title":"Eur. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.eururo.2007.09.034","article-title":"Neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre","volume":"53","author":"Filocamo","year":"2008","journal-title":"Eur. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Jhang, J.F., and Kuo, H.C. (2016). Botulinum Toxin A and Lower Urinary Tract Dysfunction: Pathophysiology and Mechanisms of Action. Toxins, 8.","DOI":"10.3390\/toxins8040120"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Choudhury, S., Baker, M.R., Chatterjee, S., and Kumar, H. (2021). Botulinum Toxin: An Update on Pharmacology and Newer Products in Development. Toxins, 13.","DOI":"10.3390\/toxins13010058"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","article-title":"Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: A randomised, double-blind, placebo-controlled trial","volume":"60","author":"Cruz","year":"2011","journal-title":"Eur. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","article-title":"Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity","volume":"187","author":"Ginsberg","year":"2012","journal-title":"J. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Cheng, T., Shuang, W.B., Jia, D.D., Zhang, M., Tong, X.N., Yang, W.D., Jia, X.M., and Li, S. (2016). Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0159307"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0022-5347(05)64066-9","article-title":"Long-term urodynamics followup of bladder augmentation for neurogenic bladder","volume":"169","author":"Quek","year":"2003","journal-title":"J. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/nau.23849","article-title":"The effects of augmentation cystoplasty and botulinum toxin injection on patient-reported bladder function and quality of life among individuals with spinal cord injury performing clean intermittent catheterization","volume":"38","author":"Myers","year":"2019","journal-title":"Neurourol. Urodyn."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/sc.2016.49","article-title":"Botulinum toxin therapy for neurogenic detrusor hyperactivity versus augmentation enterocystoplasty: Impact on the quality of life of patients with SCI","volume":"54","author":"Anquetil","year":"2016","journal-title":"Spinal Cord."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/bju.13976","article-title":"Intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity incontinence: Do we need urodynamic investigation for outcome assessment?","volume":"120","author":"Koschorke","year":"2017","journal-title":"BJU Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.5213\/inj.1732646.323","article-title":"Efficacy and Adverse Events Associated with Use of OnabotulinumtoxinA for Treatment of Neurogenic Detrusor Overactivity: A Meta-Analysis","volume":"21","author":"Yuan","year":"2017","journal-title":"Int. Neurourol. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.juro.2011.02.004","article-title":"Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: A randomized, double-blind trial","volume":"185","author":"Herschorn","year":"2011","journal-title":"J. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.juro.2016.04.046","article-title":"Long-Term Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Who Completed 4 Years of Treatment","volume":"196","author":"Rovner","year":"2016","journal-title":"J. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/nau.23354","article-title":"Is repeat Botulinum Toxin A injection valuable for neurogenic detrusor overactivity-A systematic review and meta-analysis","volume":"37","author":"Ni","year":"2018","journal-title":"Neurourol. Urodyn."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jfma.2013.10.009","article-title":"Therapeutic outcome and patient adherence to repeated onabotulinumtoxinA detrusor injections in chronic spinal cord-injured patients and neurogenic detrusor overactivity","volume":"114","author":"Chen","year":"2015","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/nau.23205","article-title":"Long-term effectiveness and complication rates of bladder augmentation in patients with neurogenic bladder dysfunction: A systematic review","volume":"36","author":"Hoen","year":"2017","journal-title":"Neurourol. Urodyn."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/nau.23339","article-title":"A real-world experience with augmentation enterocystoplasty-High patient satisfaction with high complication rates","volume":"37","author":"Wu","year":"2018","journal-title":"Neurourol. Urodyn."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1007\/s00345-019-02919-z","article-title":"Augmentation cystoplasty in the patient with neurogenic bladder","volume":"38","author":"Cheng","year":"2020","journal-title":"World J. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol. Urodyn."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1002\/nau.22637","article-title":"Chapter 6: Practical aspects of administration of onabotulinumtoxinA","volume":"33","author":"Rovner","year":"2014","journal-title":"Neurourol. Urodyn."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0022-5347(17)42283-X","article-title":"The Ileal Neobladder","volume":"139","author":"Hautmann","year":"1988","journal-title":"J. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0929-6646(09)60095-4","article-title":"Long-term Outcomes of Augmentation Enterocystoplasty with an Ileal Segment in Patients with Spinal Cord Injury","volume":"108","author":"Chen","year":"2009","journal-title":"J. Formos. Med. Assoc."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/14\/1\/47\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:14:43Z","timestamp":1760364883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/14\/1\/47"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,10]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["toxins14010047"],"URL":"https:\/\/doi.org\/10.3390\/toxins14010047","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,10]]}}}